Imaging the Neural Network Connectivity on Patients With Mild Cognitive Impairment
NCT ID: NCT01927653
Last Updated: 2018-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
108 participants
OBSERVATIONAL
2011-01-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. The diffusion MRI could provide an improved diagnosis of Alzheimer's Disease and Mild cognitive Impairment.
Explanation:
The deposition of the macromolecules such as beta amyloid in the brain and the associated neuron death of the patient could lead to observable changes in tissue microenvironment. The related changes would lead to alterations in either the amplitude or distribution of water diffusion. In turn it could be detected in diffusion tensor and kurtosis.
2. aMCI is a preclinical state of AD and dMCI is from a different etiology, which can be differentially diagnosis by MRI. Diffusion Imaging could help to predict the clinical outcome Explanation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Developmental Trajectory of Brain Structural Connectivity and Cognitive Function From Childhood to Adulthood
NCT01677793
Brain Network Characteristics in Patients With Disorders of Consciousness
NCT05558670
Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS
NCT05996575
Synaptic Injury and Functional Connectivity in Alzheimer's Disease
NCT03300726
Imaging of New Learning in Severe Alzheimer's Disease Patients
NCT01839422
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The subjects will be divided into 3 groups: 30 patients with amnestic MCI, 30 with dysexecutive MCI and 30 healthy age-matched normal controls. Comprehensive neuropsychological examinations will be performed after detailed clinical history and physical screening, including Mini-Mental Status Examination, Clinical Dementia Rating and the Cognitive Abilities Screening Instrument. Successful candidate will be examined by 3T MRI, including diffusion imaging and high resolution T1 weighted anatomical images.
The current project proposed to examine the sensitivity and specificity of diffusion Magnetic Resonance Imaging, in the diagnosis of MCI and differential diagnosis of two subtypes. Both the conventional tensor derived indices and diffusion kurtosis will be compared. This is due to the fact that in a recently publication in Radiology, we reported an improved diagnostic performance on neurodegenerative disease from diffusion kurtosis than diffusion tensor. Secondly we will examine the regional changes of diffusion properties and correlated with the white matter involvement in patients. High resolution track density images will be implemented and compared with the susceptibility weighted imaging in an effort to address the underlying changes in pathophysiology. In the third year, the prognostic value of diffusion MRI will be determined. The optimal cutoff value of diffusion MRI in the prediction of conversion to Alzheimer's disease will be reported. The diffusion properties in patients with early conversion (the 2nd year) and late conversion (the 3rd year) will be compared.
It is expected that changes in diffusion can be used as an image based surrogate marker during the neurodegenerative process. The new insight into the temporal evolution of the diffusion MRI might help to understand the underlying etiology and pathophysiology between the amnestic and dysexecutive MCI patients, which can contribute to an early intervention strategy and might ultimately lead to an effective treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The patients with amnestic MCI
The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:
1. memory complaint
2. normal general cognition
3. normal activities of daily living
4. not demented
No interventions assigned to this group
The patients with dysexecutive MCI
The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:
1. relatively focal executive dysfunction
2. Within reference range on tests of memory, language and visuospatial skills
3. normal general cognition
4. normal activities of daily living
5. not demented
No interventions assigned to this group
The healthy volunteers
The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:
1. Age and gender matched healthy subjects without significant neuropsychiatric disorder
2. Able to understand and provide signed informed consent
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:
1. memory complaint
2. normal general cognition
3. normal activities of daily living
4. not demented
The patients with dysexecutive MCI
The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:
1. relatively focal executive dysfunction
2. Within reference range on tests of memory, language and visuospatial skills
3. normal general cognition
4. normal activities of daily living
5. not demented
The healthy volunteers
The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:
1. Age and gender matched healthy subjects without significant neuropsychiatric disorder
2. Able to understand and provide signed informed consent
Exclusion Criteria
2. Implantation of intracranial metal device.
3. Other major systemic disease, such as renal failure, heart failure, stroke, AMI/unstable angina, poor controlled diabetes mellitus, poor controlled hypertension.
4. Alcohol or drug abuse
5. Meet the criteria for dementia ( DSM-IV )
6. History of neurological disorder
7. Current psychiatrical illness
8. Head trauma with loss of consciousness greater than 10 minutes
9. Severe sensory deficit
10. Taking medication that affect cognition
11. Vascular lesion on MRI with Longstreth grade \>=4
12. Structural abnormalities that could produce dementia, such as cortical infarction, tumor, or subdural hematoma
13. Treatments or concurrent illnesses other than Alzheimer disease that interfered with cognitive function.
Conversion Criteria
Patient with AD is not an enrolling group. The criteria as the MCI patients converted to is defined by NINCDS-ADRDA Criteria and CDR=0.5, 1 or 2. The diagnosis is based on the following:
1. CDR = 0.5, 1.0 or 2.0. For those of CDR 0.5, the diagnosis of MCI or AD depends on the judgment of the investigators on the level of clinical, ADL and neuropsychological impairment.
2. Probable AD defined by NINCDS/ADRDA criteria.
3. Caregiver/informant to accompany patient to all scheduled visits.
4. HAM-D rating scale score of 12 on the 17-item scale(19) or Cornell Scale for Depression in Dementia (CSDD) score\<8(20).
55 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chang Gung Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wang . Jiun-Jie
Study Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiun-Jie Wang, PhD
Role: PRINCIPAL_INVESTIGATOR
ChangGung University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ChangGung Memorial Hospital, Linkou
Taoyuan District, Taiwan, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
98-3628B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.